Abstract:Oral insulin delivery has received the most attention in insulin formulations due to its high patient compliance and, more importantly, to its potential to mimic the physiologic insulin secretion seen in non-diabetic individuals. However, oral insulin delivery has two major limitations: the enzymatic barrier that leads to rapid insulin degradation, and the mucosal barrier that limits insulin’s bioavailability. Several approaches have been actively pursued to circumvent the enzyme barrier, with some of them receiving promising results. Yet, thus far there has been no major success in overcoming the mucosal barrier, which is the main cause in undercutting insulin’s oral bioavailability. In this review of our group’s research, an innovative silica-based, mucoadhesive oral insulin formulation with encapsulated-insulin/cell penetrating peptide (CPP) to overcome both enzyme and mucosal barriers is discussed, and the preliminary and convincing results to confirm the plausibility of this oral insulin delivery system are reviewed. In vitro studies demonstrated that the CPP-insulin conjugates could facilitate cellular uptake of insulin while keeping insulin’s biologic functions intact. It was also confirmed that low molecular weight protamine (LMWP) behaves like a CPP peptide, with a cell translocation potency equivalent to that of the widely studied TAT. The mucoadhesive properties of the produced silica-chitosan composites could be controlled by varying both the pH and composition; the composite consisting of chitosan (25 wt-%) and silica (75 wt-%) exhibited the greatest mucoadhesion at gastric pH. Furthermore, drug release from the composite network could also be regulated by altering the chitosan content. Overall, the universal applicability of those technologies could lead to development of a generic platform for oral delivery of many other bioactive compounds, especially for peptide or protein drugs which inevitably encounter the poor bioavailability issues.

Supramolecular Assembly of Cp1-11 Peptide and Insulin for Rapid-Acting Formulation

Insulin and Its Single-Chain Analogue

Cp1-11 Peptide/insulin Complex Loaded Ph-Responsive Nanoparticles with Enhanced Oral Bioactivity.

Supramolecular Approaches for Insulin Stabilization Without Prolonged Duration of Action

Supramolecular Nanoparticles of Insulin and Pentapeptide for Inhibition of Fibrillation and Controlled Release

Supramolecular Protein Engineering: DESIGN OF ZINC-STAPLED INSULIN HEXAMERS AS A LONG ACTING DEPOT

Self-assembled Oligomeric Procyanidin-Insulin Hybrid Nanoparticles: a Novel Strategy for Controllable Insulin Delivery.

Efficient Encapsulation of Insulin by Giant Macrocycle as a Powerful Approach to the Inhibition of Its Fibrillation

Injectable Self-Assembled Peptide Hydrogels for Glucose-Mediated Insulin Delivery

Overcoming Oral Insulin Delivery Barriers: Application of Cell Penetrating Peptide and Silica-Based Nanoporous Composites

An orally administered glucose-responsive polymeric complex for high-efficiency and safe delivery of insulin in mice and pigs

Stable Monomeric Insulin Formulations Enabled by Supramolecular PEGylation of Insulin Analogues

A Co-Formulation of Supramolecularly Stabilized Insulin and Pramlintide Enhances Mealtime Glucagon Suppression in Diabetic Pigs.

Surface Adsorption-Mediated Ultrahigh Efficient Peptide Encapsulation with a Precise Ratiometric Control for Type 1 and 2 Diabetic Therapy.

Cell -penetrating peptide enhanced insulin buccal absorption

The Use of Low Molecular Weight Protamine Chemical Chimera to Enhance Monomeric Insulin Intestinal Absorption

Preparation and characterization of CS/γ-PGA/PC complex nanoparticles for insulin oral delivery

Supramolecular Nanofibers with Superior Bioactivity to Insulin-Like Growth Factor-I.

Nanoparticles induced by embedding self-assembling cassette into glucagon-like peptide 1 for improving in vivo stability.

In Situ Rearranged Multifunctional Lipid Nanoparticles Via Synergistic Potentiation for Oral Insulin Delivery.

A cell-penetrating peptide conjugated carboxymethyl-β-cyclodextrin to improve intestinal absorption of insulin.